Alzheimer's disease staging using only five biomarkers related to amyloid-β and tau pathologies and measured with a single sample of cerebrospinal fluid may help with stratification and prognostication in the clinical setting and in clinical trials (Wu, 2024). The gene discussed is MAPT; the disease is Alzheimer disease.